CA2263675C - Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders - Google Patents

Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders Download PDF

Info

Publication number
CA2263675C
CA2263675C CA2263675A CA2263675A CA2263675C CA 2263675 C CA2263675 C CA 2263675C CA 2263675 A CA2263675 A CA 2263675A CA 2263675 A CA2263675 A CA 2263675A CA 2263675 C CA2263675 C CA 2263675C
Authority
CA
Canada
Prior art keywords
viral
cell
cells
agent
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2263675A
Other languages
English (en)
French (fr)
Other versions
CA2263675A1 (en
Inventor
Douglas V. Faller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/687,671 external-priority patent/US6197743B1/en
Priority claimed from US08/687,670 external-priority patent/US5939456A/en
Application filed by Boston University filed Critical Boston University
Publication of CA2263675A1 publication Critical patent/CA2263675A1/en
Application granted granted Critical
Publication of CA2263675C publication Critical patent/CA2263675C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2263675A 1996-07-26 1997-07-28 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders Expired - Fee Related CA2263675C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/687,671 US6197743B1 (en) 1996-07-26 1996-07-26 Compositions and methods for the treatment of viral disorders
US08/687,671 1996-07-26
US08/687,670 US5939456A (en) 1996-07-26 1996-07-26 Pulsed administration of compositions for the treatment of blood disorders
US08/687,670 1996-07-26
PCT/US1997/012818 WO1998004290A2 (en) 1996-07-26 1997-07-28 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders

Publications (2)

Publication Number Publication Date
CA2263675A1 CA2263675A1 (en) 1998-02-05
CA2263675C true CA2263675C (en) 2010-04-13

Family

ID=27104047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2263675A Expired - Fee Related CA2263675C (en) 1996-07-26 1997-07-28 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders

Country Status (5)

Country Link
EP (4) EP1886677A1 (https=)
JP (1) JP2001527517A (https=)
AU (1) AU3889197A (https=)
CA (1) CA2263675C (https=)
WO (1) WO1998004290A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
AU2685399A (en) * 1998-03-26 1999-10-18 Julianna Lisziewicz Method of rendering a human immunodeficiency virus population replication incompetent (in vivo)
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
KR100788970B1 (ko) * 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
WO2001082927A1 (en) * 2000-05-02 2001-11-08 Lead Chemical Co., Ltd Antibiral compositions containing phorbol derivatives as the main active ingredient
HU230252B1 (hu) 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2046736B1 (en) * 2006-07-27 2019-06-12 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
JP5031778B2 (ja) * 2007-02-14 2012-09-26 株式会社カネカ 光学活性な２−（アロイルオキシ）プロピオン酸を用いたアミン化合物の製造方法
WO2008128299A1 (en) * 2007-04-24 2008-10-30 Murdoch Childrens Research Institute Therapeutic protocol for treating hemoglobinopathy
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
EP2276478A4 (en) * 2008-04-11 2012-03-07 Aids Res Alliance METHOD FOR THE ADMINISTRATION OF PROSTRATIN AND STRUCTURAL ANALOGUE THEREOF
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) * 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
JP2013523795A (ja) 2010-04-06 2013-06-17 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 植物のストレス耐性を増強させるための４−フェニル酪酸及び／又はその塩の使用
KR101293620B1 (ko) 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
BR112015022854A2 (pt) 2013-03-14 2017-07-18 Alkermes Pharma Ireland Ltd pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
WO2018140934A1 (en) * 2017-01-30 2018-08-02 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
US12419884B2 (en) 2018-08-06 2025-09-23 Brigham Young University Compositions and methods for treating iron overload
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
EP3937922A4 (en) * 2019-03-14 2022-11-30 Hemoshear Therapeutics, Inc. Methods of treating organic acidemias
CA3142142A1 (en) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
AU2021336289A1 (en) * 2020-09-01 2023-05-04 I2O Therapeutics, Inc. Ionic liquid formulations for treating diabetes
CN113621577B (zh) * 2021-08-05 2023-03-10 河南普诺易生物制品研究院有限公司 人源化hek293细胞系表达重组蛋白用培养基添加剂、重组乙肝疫苗、表达方法
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
CN120241679B (zh) * 2025-03-06 2025-12-05 华南农业大学 方酸类化合物在制备抗弓形虫病药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US496525A (en) 1893-05-02 Eugene gillet de montmore
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
FR2508797B1 (fr) * 1981-07-03 1986-03-14 Charles Chany Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique
US4704402A (en) 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5025029A (en) 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5032507A (en) 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis
ES2061963T3 (es) * 1988-01-13 1994-12-16 Univ Arizona State Briostatinas inmunomoduladoras.
US4997815A (en) 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
CA2038945A1 (en) * 1989-08-01 1991-02-02 Norman D. Weiner Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
EP0546261A3 (en) * 1991-09-12 1993-08-11 American Cyanamid Company Method of treating latent herpes viral infections
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
EP0567613B1 (en) * 1991-10-21 2002-02-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Compositions for therapy and prevention of cancer
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
IL110380A0 (en) * 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders

Also Published As

Publication number Publication date
CA2263675A1 (en) 1998-02-05
EP1886677A1 (en) 2008-02-13
EP2298350A2 (en) 2011-03-23
WO1998004290A3 (en) 1998-08-13
AU3889197A (en) 1998-02-20
WO1998004290A2 (en) 1998-02-05
EP1611885A1 (en) 2006-01-04
EP0969869A2 (en) 2000-01-12
EP1611885A8 (en) 2007-10-24
EP2298350A3 (en) 2011-06-08
JP2001527517A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
CA2263675C (en) Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
US6677302B2 (en) Compositions and methods for the treatment of viral disorders
US20230346788A1 (en) Methods for treating viral disorders
US6011000A (en) Compositions for the treatment of blood disorders
US20090082444A1 (en) Compositions for the Treatment of Blood Disorders
US6451334B2 (en) Compositions and administration of compositions for the treatment of blood disorders
US5939456A (en) Pulsed administration of compositions for the treatment of blood disorders
WO1996027369A9 (en) Compositions for the treatment of blood disorders
CN100427081C (zh) 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物
ES2312884T3 (es) Composiciones antivirales que comprenden derivados de acido fenilacetico.
KR940002820B1 (ko) Hiv 감염 관련 질병의 치료를 위한 약제 조성물
US6403647B1 (en) Pulsed administration of compositions for the treatment of blood disorders
JP7541054B2 (ja) 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
HK1110230A (en) Use of an inducing agent for the treatment of blood, viral and cellular disorders
US7910624B1 (en) Compositions for the treatment of blood disorders
AU5277902A (en) Compositions for the treatment of blood disorders
AU3252800A (en) Compositions for the treatment of blood disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130730